Koo, while I obviously agree that the financial side is more than pressing, that 'article' is the announcement of publication in a respected journal regarding another potentially lucrative avenue (NAFLD) for Apabetalone. Further it being retweeted by Jon Kastelein and other respected cardiovascular professionals goes a long way to further supporting the science at RVX.  Big pharma listens to people like Kastelein and Kausik Ray and given RVX's abysmal management/board, especially related to science, the company needs all the help it can get. Additional financial potential for Apabetalone is only going to help get BP more interested. To me this is important given that, IMO, we will likely not see management acting in a proactive way to initiate the sale process of the company. 

Hopefully we will soon hear something concrete about the FDA meeting. Short term perhaps management could then get a small, above market investment by a pharma interested in the science (similar to what Pfizer did with Trillium before they eventually bought the company) which might then rekindle the markets interest. I know that is probably expecting a lot from business management that has yet to show even a glimmer of competence.